Logo image of EVO

EVOTEC SE - SPON ADR (EVO) Stock Fundamental Analysis

USA - NASDAQ:EVO - US30050E1055 - ADR

3.64 USD
-0.09 (-2.41%)
Last: 9/19/2025, 8:01:20 PM
3.64 USD
0 (0%)
After Hours: 9/19/2025, 8:01:20 PM
Fundamental Rating

2

Taking everything into account, EVO scores 2 out of 10 in our fundamental rating. EVO was compared to 56 industry peers in the Life Sciences Tools & Services industry. EVO may be in some trouble as it scores bad on both profitability and health. EVO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year EVO has reported negative net income.
EVO had a positive operating cash flow in the past year.
In multiple years EVO reported negative net income over the last 5 years.
Each year in the past 5 years EVO had a positive operating cash flow.
EVO Yearly Net Income VS EBIT VS OCF VS FCFEVO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

1.2 Ratios

The Return On Assets of EVO (-8.60%) is comparable to the rest of the industry.
The Return On Equity of EVO (-18.39%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -8.6%
ROE -18.39%
ROIC N/A
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
EVO Yearly ROA, ROE, ROICEVO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

Looking at the Gross Margin, with a value of 12.89%, EVO is doing worse than 85.71% of the companies in the same industry.
EVO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 12.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
EVO Yearly Profit, Operating, Gross MarginsEVO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20

More info and screens

3

2. Health

2.1 Basic Checks

EVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for EVO has been increased compared to 1 year ago.
The number of shares outstanding for EVO has been increased compared to 5 years ago.
EVO has a better debt/assets ratio than last year.
EVO Yearly Shares OutstandingEVO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M
EVO Yearly Total Debt VS Total AssetsEVO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B 2B

2.2 Solvency

EVO has an Altman-Z score of 0.52. This is a bad value and indicates that EVO is not financially healthy and even has some risk of bankruptcy.
EVO has a worse Altman-Z score (0.52) than 64.29% of its industry peers.
EVO has a debt to FCF ratio of 37.11. This is a negative value and a sign of low solvency as EVO would need 37.11 years to pay back of all of its debts.
The Debt to FCF ratio of EVO (37.11) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.42 indicates that EVO is not too dependend on debt financing.
EVO has a Debt to Equity ratio (0.42) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF 37.11
Altman-Z 0.52
ROIC/WACCN/A
WACC7.16%
EVO Yearly LT Debt VS Equity VS FCFEVO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

EVO has a Current Ratio of 1.58. This is a normal value and indicates that EVO is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of EVO (1.58) is worse than 73.21% of its industry peers.
EVO has a Quick Ratio of 1.49. This is a normal value and indicates that EVO is financially healthy and should not expect problems in meeting its short term obligations.
EVO has a Quick ratio of 1.49. This is in the lower half of the industry: EVO underperforms 60.71% of its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.49
EVO Yearly Current Assets VS Current LiabilitesEVO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

3

3. Growth

3.1 Past

The earnings per share for EVO have decreased strongly by -136.17% in the last year.
Looking at the last year, EVO shows a decrease in Revenue. The Revenue has decreased by -1.41% in the last year.
The Revenue has been growing by 12.29% on average over the past years. This is quite good.
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-5.98%

3.2 Future

Based on estimates for the next years, EVO will show a very strong growth in Earnings Per Share. The EPS will grow by 20.11% on average per year.
The Revenue is expected to grow by 7.02% on average over the next years.
EPS Next Y57.58%
EPS Next 2Y35.2%
EPS Next 3Y27.47%
EPS Next 5Y20.11%
Revenue Next Year-1.21%
Revenue Next 2Y4.03%
Revenue Next 3Y6.51%
Revenue Next 5Y7.02%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
EVO Yearly Revenue VS EstimatesEVO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
EVO Yearly EPS VS EstimatesEVO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

EVO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVO Price Earnings VS Forward Price EarningsEVO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EVO is on the same level as its industry peers.
EVO's Price/Free Cash Flow ratio is in line with the industry average.
Industry RankSector Rank
P/FCF 88.45
EV/EBITDA 83.38
EVO Per share dataEVO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as EVO's earnings are expected to grow with 27.47% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.2%
EPS Next 3Y27.47%

More info and screens

0

5. Dividend

5.1 Amount

EVO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOTEC SE - SPON ADR

NASDAQ:EVO (9/19/2025, 8:01:20 PM)

After market: 3.64 0 (0%)

3.64

-0.09 (-2.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)08-13 2025-08-13/bmo
Earnings (Next)11-05 2025-11-05/bmo
Inst Owners57.36%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap1.29B
Analysts76.67
Price Target5.65 (55.22%)
Short Float %0.23%
Short Ratio12.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-4.94%
Min Revenue beat(2)-5.1%
Max Revenue beat(2)-4.77%
Revenue beat(4)0
Avg Revenue beat(4)-4.23%
Min Revenue beat(4)-6.12%
Max Revenue beat(4)-0.93%
Revenue beat(8)2
Avg Revenue beat(8)-0.61%
Revenue beat(12)4
Avg Revenue beat(12)1.62%
Revenue beat(16)8
Avg Revenue beat(16)3.57%
PT rev (1m)0.88%
PT rev (3m)-6.08%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-42.91%
EPS NY rev (1m)0%
EPS NY rev (3m)-63.25%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.9%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-8.8%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.42
P/FCF 88.45
P/OCF 9.87
P/B 1.3
P/tB 2.03
EV/EBITDA 83.38
EPS(TTM)-0.65
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)0.04
FCFY1.13%
OCF(TTM)0.37
OCFY10.13%
SpS2.57
BVpS2.8
TBVpS1.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.6%
ROE -18.39%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 12.89%
FCFM 1.6%
ROA(3y)-7.25%
ROA(5y)-2.34%
ROE(3y)-14.29%
ROE(5y)-5.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-16.23%
GM growth 5Y-13.5%
F-Score4
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.42
Debt/FCF 37.11
Debt/EBITDA 26.48
Cap/Depr 97.54%
Cap/Sales 12.75%
Interest Coverage N/A
Cash Conversion 831.71%
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.49
Altman-Z 0.52
F-Score4
WACC7.16%
ROIC/WACCN/A
Cap/Depr(3y)186.39%
Cap/Depr(5y)182.37%
Cap/Sales(3y)22.79%
Cap/Sales(5y)21.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-136.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%55.56%
EPS Next Y57.58%
EPS Next 2Y35.2%
EPS Next 3Y27.47%
EPS Next 5Y20.11%
Revenue 1Y (TTM)-1.41%
Revenue growth 3Y8.85%
Revenue growth 5Y12.29%
Sales Q2Q%-5.98%
Revenue Next Year-1.21%
Revenue Next 2Y4.03%
Revenue Next 3Y6.51%
Revenue Next 5Y7.02%
EBIT growth 1Y-20.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year147.54%
EBIT Next 3Y53.1%
EBIT Next 5Y34.31%
FCF growth 1Y105.04%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y359%
OCF growth 3Y-46.98%
OCF growth 5Y-15.47%